GlyNAC Supplementation Targets Glutathione, Mitochondria and Muscle in Older HIV Patients
A 12-week GlyNAC trial in older HIV patients tests whether restoring glutathione improves strength, body composition, cognition, and mitochondrial energy.
Summary
Older adults living with HIV often have chronically low glutathione (GSH), a master antioxidant, due to shortfalls in two amino acid precursors — glycine and cysteine. Prior short-term work showed that combining glycine with N-acetylcysteine (GlyNAC) for two weeks partially restored red blood cell GSH and improved mitochondrial fuel burning. This Baylor College of Medicine Phase 1 trial extends supplementation to 12 weeks and tracks a broader set of outcomes: GSH levels, body composition, muscle strength, physical function, quality of life, mitochondrial energetics, blood lipids, oxidative stress, protein and glucose metabolism, and cognitive performance. A two-month washout period after supplementation will reveal how durable the benefits are. Results could clarify whether GlyNAC is a practical nutritional strategy for preserving healthspan in an aging HIV population.
Detailed Summary
Glutathione (GSH) is the body's most abundant intracellular antioxidant, and its depletion accelerates many hallmarks of biological aging — mitochondrial dysfunction, oxidative stress, inflammation, and muscle loss. HIV infection compounds this problem: older patients with HIV are often severely GSH-deficient because the condition depletes cysteine and glycine, the two amino acids needed for GSH synthesis. The result is a state of accelerated aging layered on top of a chronic viral illness.
Researchers at Baylor College of Medicine conducted a Phase 1 clinical trial (NCT02348775) to determine whether 12 weeks of GlyNAC supplementation — glycine combined with N-acetylcysteine as a cysteine donor — could comprehensively reverse this deficit. The study builds on earlier two-week pilot data showing partial restoration of red blood cell GSH and improved mitochondrial oxidative fuel metabolism in the same population.
The trial measured an expansive array of outcomes: GSH concentrations in red blood cells, anthropometry and body composition, muscle strength and physical function, quality of life, mitochondrial energetics, lipid and oxidative stress biomarkers, protein and glucose metabolism, and neurocognitive testing. Following the three-month supplementation phase, participants underwent a two-month washout to assess how long any improvements persisted without continued dosing.
The clinical implications are substantial. Mitochondrial dysfunction, loss of muscle strength, dyslipidemia, cognitive decline, and elevated oxidative stress are not unique to HIV — they are universal features of aging. If GlyNAC reliably corrects GSH deficiency and reverses these deficits in an accelerated-aging population, it becomes a compelling candidate for broader longevity supplementation strategies, particularly given its low cost and favorable safety profile.
Key caveats apply. This was a Phase 1 trial with a primary safety and feasibility mandate. The summary is based on the abstract alone; full results, sample size, and statistical details are not available here. The HIV population may limit generalizability to otherwise healthy older adults.
Key Findings
- 12-week GlyNAC supplementation tested for GSH restoration beyond the partial correction seen at 2 weeks.
- Trial tracked mitochondrial energetics, muscle strength, body composition, and cognition simultaneously.
- A 2-month washout phase was included to assess durability of GSH and functional improvements.
- Dyslipidemia and oxidative stress markers were measured, linking GSH to cardiometabolic aging.
- Earlier pilot data showed improved muscle strength alongside GSH restoration — this trial aimed to confirm and extend that finding.
Methodology
Phase 1 clinical trial enrolling older HIV-positive patients with erythrocyte glutathione deficiency, sponsored by Baylor College of Medicine. Intervention was 12 weeks of oral GlyNAC (glycine plus N-acetylcysteine), followed by a 2-month washout period. Outcomes spanned biochemical, metabolic, functional, and neurocognitive domains.
Study Limitations
Summary is based on the abstract only; full methodology, sample size, statistical results, and adverse event data are not available. Phase 1 designation prioritizes safety and feasibility over efficacy proof. Findings in older adults with HIV may not generalize directly to the broader aging population without HIV comorbidity.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: